Tyfel-Paluszek Justyna, Kułaga Aleksandra, Mikunda Aleksandra, Pominkiewicz Łukasz, Łach Jacek, Płazak Wojciech
Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital, Prądnicka 80, Kraków, 31-202, Poland.
Department of Coronary Artery Disease and Heart Failure, Jagiellonian University Medical College, John Paul II Hospital, Kraków, Poland.
Sleep Breath. 2025 Jan 27;29(1):90. doi: 10.1007/s11325-025-03245-y.
Obstructive sleep apnoea (OSA) may lead to heart rhythm abnormalities including bradycardia. Our aim was to ascertain clinical and echocardiographic parameters in patients with OSA in whom severe bradycardia was detected in an outpatient setting, as well as to evaluate the efficacy of CPAP therapy on heart rate normalization at the early stages of treatment.
Fifteen patients mild, moderate or severe OSA and concomitant bradycardia were enrolled. A standard non-invasive diagnostic assessment protocol was followed, including blood tests and echocardiography. The 24-hour Holter ECG was performed to confirm the presence of bradycardia and determine its subtype. Then CPAP therapy was commenced. Throughout the hospitalisation, continued cardiac monitoring was used in all patients, and 3-4 days following CPAP therapy commencement, a follow-up 24-hour Holter ECG was performed.
Out of 15 patients observed, 3 patients did not consent to CPAP therapy, and one patient had to undergo emergency pacemaker implantation before he was started on CPAP. A complete resolution of bradycardia and cardiac conduction abnormalities was achieved in the remaining 11 patients by day 4. of treatment. The mean lowest recorded HR was 52.7 bpm as compared to 33.9 bpm before CPAP therapy commencement (p < 0.0002). Sinus pauses exceeding 2.5s were not detected in any of those patients.
OSA may be comorbid with and precipitate severe bradycardia. CPAP therapy enabled rapid resolution of bradycardia in more than 80% of our cohort, which may potentially prevent pacemaker implantation provided they remain compliant.
阻塞性睡眠呼吸暂停(OSA)可能导致包括心动过缓在内的心律异常。我们的目的是确定在门诊环境中检测到严重心动过缓的OSA患者的临床和超声心动图参数,并评估持续气道正压通气(CPAP)治疗在治疗早期对心率恢复正常的疗效。
招募了15例轻度、中度或重度OSA并伴有心动过缓的患者。遵循标准的非侵入性诊断评估方案,包括血液检查和超声心动图检查。进行24小时动态心电图检查以确认心动过缓的存在并确定其亚型。然后开始CPAP治疗。在整个住院期间,所有患者均持续进行心脏监测,并在开始CPAP治疗3 - 4天后进行随访24小时动态心电图检查。
在观察的15例患者中,3例患者不同意接受CPAP治疗,1例患者在开始CPAP治疗前必须接受紧急起搏器植入。其余11例患者在治疗第4天时心动过缓和心脏传导异常完全消失。记录的最低平均心率为52.7次/分钟,而在开始CPAP治疗前为33.9次/分钟(p < 0.0002)。在这些患者中均未检测到超过2.5秒的窦性停搏。
OSA可能与严重心动过缓合并并引发严重心动过缓。CPAP治疗使我们队列中超过80%的患者心动过缓迅速得到缓解,这可能潜在地避免起搏器植入,前提是他们保持依从性。